Requests · The University of Texas at Arlington
Institute of Biomanufacturing and Precision Medicine for North Texas
Priority 1 · one of 3 items in the The University of Texas at Arlington's request for 2028-29 · The item begins on page 86 of the request
This is a request, not an appropriation.
What is asked
| 2028 | 2029 | Two years | |
|---|---|---|---|
| All funds | $9,000,000 | $9,000,000 | $18,000,000 |
| Of which general revenue and general revenue-dedicated | $9,000,000 | $9,000,000 | $18,000,000 |
| Positions (full-time equivalents) | 50.0 | 50.0 |
How it would be financed
| Method of financing, as the request prints it | 2028 | 2029 |
|---|---|---|
| 1 General Revenue Fund | $9,000,000 | $9,000,000 |
| Total, as the request prints it | $9,000,000 | $9,000,000 |
Where it would land
The strategies this item would add to, numbered as the request numbers them, beside what each is appropriated in the current budget (2026-27 Act). One column is an appropriation and the other a request made on top of a base request not shown here, so the two are not subtracted.
| Strategy | Asked 2028 | Asked 2029 | Positions | Appropriated 2026 | Appropriated 2027 |
|---|---|---|---|---|---|
| 03-02-02 Institute of Biomanufacturing and Precision Medicine for North Texas | $9,000,000 | $9,000,000 | 50.0 | No strategy matched in the current budget | |
A strategy is matched by its name. Where none is matched, the strategy may be new, or may be in the current budget under a different name.
After 2029
| The agency's estimate | 2030 | 2031 | 2032 | Three years |
|---|---|---|---|---|
| All funds | $9,000,000 | $9,000,000 | $9,000,000 | $27,000,000 |
In the agency's words: Sustaining the work of the Institute will require continued funding of the program at the same level of support as the 2028-29 request.
The agency's justification
UTA requests $18.0 million for the 2028-29 biennium for IMPRINT, the Institute of Biomanufacturing and Precision Medicine for North Texas. Building upon the partial funding received from the Legislature beginning in the 2024-25 biennium, IMPRINT advances Texas’ health and economic priorities by accelerating biomedical discovery into therapeutic development, scalable biomanufacturing, and workforce preparation.
The Institute of Biomanufacturing and Precision Medicine for North Texas (IMPRINT) develops and operates the infrastructure, partnerships, and translational capabilities needed to move biomedical discoveries from academic research to clinical and commercial impact. The institute addresses a critical gap in the life sciences ecosystem: the distance between promising scientific discoveries and the commercially viable therapeutic candidates, manufacturing capabilities, and companies required to deliver those innovations to patients. Through strategic collaborations with academic institutions, healthcare systems, and industry leaders across Texas, IMPRINT supports the full pathway from discovery and development through manufacturing , regulatory readiness, and market translation.
IMPRINT is helping establish a unique Texas capability: an integrated translational-to-commercialization ecosystem for therapeutics and precision medicine that spans discovery, development, manufacturing, and commercialization. This infrastructure generates venture-backable assets, enables startup formation, strengthens innovation hubs such as Pegasus Park, expands biotechnology capacity across North Texas, and creates shared resources that benefit the broader life sciences ecosystem. By connecting innovation with commercialization, IMPRINT advances patient care while strengthening Texas' competitiveness in biotechnology, advanced manufacturing, and economic development.
External and internal factors
For additional information, see Schedule 9, Non-Formula Support
As marked in the request
- Has an information technology part: No
- Costs anticipated after the two budget years: Yes
- Involves contracts over $50,000: No